Negative feedback control is a common strategy that evolved in many biosynthetic pathways, where the final biosynthetic product allosterically inhibits the first and often flux-controlling enzyme of the pathway.^[@ref1],[@ref2]^ The biosynthesis of histidine showcases a classical example of negative feedback regulation of biochemical pathways via allosteric inhibition.^[@ref3]^ The pathway starts with the Mg^2+^-dependent and reversible nucleophilic attack of adenosine 5′-triphosphate (ATP) on 5-phospho-α-[d]{.smallcaps}-ribosyl-1-pyrophosphate (PRPP) to generate *N*^1^-(5-phospho-β-[d]{.smallcaps}-ribosyl)-ATP (PRATP) and inorganic pyrophosphate (PP~i~), catalyzed by the flux-controlling enzyme ATP phosphoribosyltransferase (ATPPRT, EC 2.4.2.17) ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref4]^ After eight subsequent reactions, PRATP is converted to [l]{.smallcaps}-histidine, which allosterically inhibits ATPPRT.^[@ref5]^

![ATPPRT-Catalyzed Reaction Is Inhibited by Histidine](bi-2019-002824_0008){#sch1}

ATPPRT is a model system for interrogation of the allosteric control of enzyme catalysis,^[@ref6]−[@ref11]^ with applications in synthetic biology^[@ref12],[@ref13]^ and antibiotic discovery.^[@ref14],[@ref15]^ Accordingly, allosteric inhibition of ATPPRT by histidine has been extensively investigated with the homohexameric long form of the enzyme (HisG~L~), which is present in most histidine-synthesizing organisms.^[@ref3],[@ref9],[@ref14],[@ref16]−[@ref18]^ On the other hand, inhibition of short-form ATPPRT, found instead in archaea and some eubacteria, is poorly understood.

Short-form ATPPRTs assemble in a hetero-octamer consisting of four regulatory subunits flanked on each side by a dimer of catalytic subunits. The active site is found solely within HisG~S~, a version of HisG~L~ in which the C-terminal domain responsible for allosteric inhibition is missing.^[@ref8],[@ref19]^ HisG~S~ on its own forms homodimers with reduced catalytic activity, and it is insensitive to histidine.^[@ref6],[@ref20]^ HisG~S~ catalysis is allosterically enhanced in the hetero-octameric ATPPRT holoenzyme by interaction with regulatory protein HisZ, a catalytically inactive paralogue of histidyl-tRNA synthetase (HisRS).^[@ref8],[@ref21]^ In the presence of histidine, however, HisZ mediates the allosteric inhibition of ATPPRT. Only one crystal structure of a short-form ATPPRT in complex with histidine has been published so far, that of the thermophile *Thermotoga maritima*, where, unexpectedly, eight molecules of histidine per hetero-octamer are found, located at the HisG~S~--HisZ interface and showing more polar interactions with the catalytic subunit than with the regulatory one.^[@ref22]^

We have recently reported the structural and kinetic basis for allosteric activation of the hetero-octameric ATPPRT from the psychrophilic bacterium *Psychrobacter arcticus* (*Pa*ATPPRT).^[@ref10],[@ref11],[@ref20]^ In the work presented here, we use steady-state and pre-steady-state kinetics and determine the crystal structure of the *Pa*ATPPRT--PRPP--histidine complex to elucidate the mechanism of allosteric inhibition of short-form ATPPRTs by histidine.

Materials and Methods {#sec2}
=====================

Materials {#sec2.1}
---------

ATP, PRPP, adenosine 5′-triphosphate (ADP), [l]{.smallcaps}-histidine, 3-(2-thienyl)-[l]{.smallcaps}-alanine (TIH), MgCl~2~, dithiothreitol (DTT), and tricine were purchased from Sigma-Aldrich. All other chemicals were purchased from readily available commercial sources. All chemicals were used without further purification. *Pa*HisG~S~, *Pa*HisZ, and *Mycobacterium tuberculosis* pyrophosphatase (*Mt*PPase) were produced as previously published.^[@ref20]^ The concentrations of *Pa*HisG~S~, *Pa*HisZ, and the *Pa*ATPPRT holoenzyme were calculated as previously described.^[@ref20]^

*Pa*HisG~S~ and *Pa*ATPPRT Activity Assay {#sec2.2}
-----------------------------------------

All assays were performed under initial rate conditions in the forward direction at 20 °C, in the presence or absence of histidine, as previously described^[@ref20]^ by monitoring the increase in absorbance at 290 nm due to the formation of PRATP (ε~290~ = 3600 M^--1^ cm^--1^)^[@ref23]^ in 1 cm path length quartz cuvettes (Hellma) in a Shimadzu UV-2600 spectrophotometer. Unless stated otherwise, for *Pa*HisG~S~ activity, the *Pa*HisG~S~ concentration was typically 2 μM, and for *Pa*ATPPRT activity, *Pa*HisG~S~ and *Pa*HisZ concentrations were 0.28 and 15 μM, respectively. Reactions were started by addition of PRPP. Control reaction mixtures lacked either ATP, PRPP, *Pa*HisG~S~, or *Pa*HisZ. Controls were also carried out to ensure that the rate did not depend on *Mt*PPase. Initial rates were also measured with saturating concentrations of both substrates in the presence or absence of 4 mM TIH. All kinetic measurements were performed at least in duplicate unless stated otherwise.

Differential Scanning Fluorimetry (DSF) {#sec2.3}
---------------------------------------

DSF measurements (λ~ex~ = 490 nm; λ~em~ = 610 nm) were performed in 96-well plates on a Stratagene Mx3005p instrument. Thermal denaturation of 9.4 μM *Pa*HisZ was assayed (50 μL) in the presence of several histidine concentrations (0--8 mM) in 100 mM tricine, 100 mM KCl, 4 mM DTT, and 15 mM MgCl~2~ (pH 8.5). Sypro Orange (5×) (Invitrogen) was added to all wells. Thermal denaturation curves were recorded over a temperature range of 25--65 °C with 1 °C min^--1^ increments. Control curves without the enzyme and were subtracted from curves with the enzyme. All measurements were carried out in quintuplicate.

*Pa*ATPPRT Saturation Kinetics with ADP and PRPP {#sec2.4}
------------------------------------------------

Initial rates for *Pa*ATPPRT (0.28 μM) were determined at saturating concentrations of one substrate and varying concentrations of the other, either ADP (0.4--5.6 mM) or PRPP (0.1--2.0 mM).

*Pa*ATPPRT Inhibition by Histidine {#sec2.5}
----------------------------------

The half-maximal inhibitory concentration of histidine was determined by measuring the initial rates for *Pa*ATPPRT (0.24 μM) in the presence of 5.6 mM ATP (or 5.6 mM ADP), 2 mM PRPP, and varying concentrations of histidine (0--320 μM). The inhibition mechanism was investigated by measuring the initial rates for *Pa*ATPPRT (0.28 μM) at saturating concentrations of one substrate and varying concentrations of the other, either ATP (0.2--2.8 mM) or PRPP (0.1--2.0 mM), with different concentrations of histidine (0--10 μM). In some instances, the lowest-concentration data point was an outlier in the double-reciprocal plot and was excluded from the fit.

Rapid Kinetics {#sec2.6}
--------------

Rapid kinetics experiments were carried out under multiple-turnover conditions by monitoring the increase in absorbance at 290 nm upon PRATP formation at 20 °C in an Applied Photophysics SX-20 stopped-flow spectrophotometer outfitted with a 5 μL mixing cell (0.5 cm path length and 0.9 ms dead time). In all experiments, each syringe contained 100 mM tricine (pH 8.5), 100 mM KCl, 4 mM DTT, 15 mM MgCl~2~, and 10 μM *Mt*PPase. For the approach to steady state in the *Pa*ATPPRT reaction, one syringe carried 38 μM *Pa*ATPPRT, 4 mM PRPP, and either 0 or 60 μM histidine, while the other carried 7 mM ATP and either 0 or 60 μM histidine. Reaction was triggered by rapidly mixing 55 μL from each syringe. The increase in absorbance was monitored in a split-time base for 1 s, with 2500 data points collected before 0.2 s and 2500 in the following 0.8 s. At least four traces were acquired for each reaction, and controls lacked PRPP. For initial rates of *Pa*ATPPRT and *Pa*HisG~S~ reactions, one syringe carried either 2--4 μM *Pa*HisG~S~ or 4 μM *Pa*ATPPRT, 4 mM PRPP, and either 0 or 1.28 mM histidine, while the other carried 11.2 mM ATP. Reaction was triggered by rapidly mixing 55 μL from each syringe. The increase in absorbance was monitored in a linear-time base for 10 s. At least four traces were acquired for each reaction, with 1000 data points collected per trace. Controls lacked PRPP.

Protein Crystallography {#sec2.7}
-----------------------

*Pa*ATPPRT crystallization was performed as previously described.^[@ref20]^ Crystals were washed in a buffer containing 10% polyethylene glycol 3350, 0.1 M bicine (pH 8.5), 50 mM MgCl~2~, 0.1 M KBr, and 4% 1,6-hexanediol and then soaked for 10 min a 1 μL drop of this solution in which PRPP and ATP had been dissolved, as previously reported.^[@ref10]^ Crystals were then transferred to a fresh drop of the soaking solution substituted with histidine and 20% 2-methyl-2,4-pentanediol for 20 s and flash-cooled in a stream of nitrogen gas at 100 K. Data were collected at beamline i24 at the Diamond Light Source (Oxfordshire, U.K.) and processed using the automated processing pipeline integrated with XDS.^[@ref24]^ The data were scaled using AIMLESS,^[@ref25]^ and the structure was determined with MOLREP^[@ref26]^ using Protein Data Bank (PDB) entry 6FTT([@ref10]) as a search model. The model, showing the full hetero-octamer in the asymmetric unit, was refined using cycles of model building with COOT^[@ref27]^ and refinement with REFMAC.^[@ref28]^ Electron density in the omit map showed the presence of histidine in the four *Pa*HisZ subunits and PRPP in the four *Pa*HisG~S~ ones. Some electron density was seen in one of the *Pa*HisG~S~ chains where in previous structures the adenine ring of ATP was observed; however, it could not be unambiguously modeled and was left empty. The final coordinates were deposited in the Protein Data Bank (entry 6R02).

Site-Directed Mutagenesis of *Pa*HisZ {#sec2.8}
-------------------------------------

Replacement of tyrosine for phenylalanine at position 263 of *Pa*HisZ was accomplished by the method of Liu and Naismith,^[@ref29]^ with primers 5′-GGCTTCCACTACCATACGGGTATTGTTTTCAACGGTTATATC-3′ and 5′-CGTATGGTAGTGGAAGCCGCTCAATTCGGTAACGTCAATG-3′. Successful mutation was confirmed by DNA sequencing (Eurofins Genomics). Y263F-*Pa*HisZ was expressed and purified by the same protocol reported for wild-type (WT) *Pa*HisZ.^[@ref20]^ ESI/MS analysis of the protein yielded a mass of 43068.9, exactly what would be expected by the loss of a hydroxyl group when compared with the mass of WT-*Pa*HisZ.^[@ref20]^ Y263F-*Pa*HisZ-based *Pa*ATPPRT was assayed for catalytic activity under initial rate conditions at 20 °C in the presence of 5.6 mM ATP and 2 mM PRPP and in the presence or absence of 320 μM histidine, along with other reaction components exactly as described for WT-*Pa*ATPPRT. Measurements were carried out in duplicate.

Analysis of Kinetic and Thermal Denaturation Data {#sec2.9}
-------------------------------------------------

Kinetic and DSF data were analyzed by the nonlinear regression function of SigmaPlot 13 (SPSS Inc.). Data points and error bars in graphs are represented as means ± the standard error, and kinetic and equilibrium constants are presented as means ± the fitting error. Substrate saturation data were fitted to [eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}. Inhibition data at fixed substrate concentrations were fitted to [eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"}, and inhibition mechanism data were fitted to [eq [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"}. In [eqs [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}--[3](#eq3){ref-type="disp-formula"}, *v* is the initial rate, *S* is the concentration of the varying substrate, *k*~cat~ is the steady-state turnover number, *K*~M~ is the apparent Michaelis constant, *E*~T~ is total enzyme concentration, *v*~i~ is the initial rate in the presence of an inhibitor, IC~50~ is the half-maximal inhibitory concentration, *h* is the Hill slope, *K*~is~ is the slope inhibition constant, and *K*~ii~ is the intercept inhibition constant. DSF thermal denaturation data were fitted to [eq [4](#eq4){ref-type="disp-formula"}](#eq4){ref-type="disp-formula"},^[@ref30]^ and *Pa*HisZ--histidine complex equilibrium dissociation data were fitted to [eq [5](#eq5){ref-type="disp-formula"}](#eq5){ref-type="disp-formula"}. In [eqs [4](#eq4){ref-type="disp-formula"}](#eq4){ref-type="disp-formula"} and [5](#eq5){ref-type="disp-formula"}, *F*~U~ is the fraction unfolded, *T* is the temperature in degrees Celsius, *T*~m~ is the melting temperature, *c* is the slope of the transition region, LL and UL are folded and unfolded baselines, respectively, *T*~m0~ is the *T*~m~ in the absence of histidine, *T*~m∞~ is the *T*~m~ at an infinite histidine concentration, *H* is the histidine concentration, and *K*~D~ is the apparent equilibrium dissociation constant for the *Pa*HisZ--histidine complex.
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Results and Discussion {#sec3}
======================

Histidine Is a Noncompetitive Inhibitor of *Pa*ATPPRT {#sec3.1}
-----------------------------------------------------

Histidine inhibits *Pa*ATPPRT with an IC~50~ of 35.5 ± 0.8 μM and an *h* of 1.30 ± 0.04 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A), both values being in close agreement with those reported for the inhibition of *M. tuberculosis* HisG~L~ ATPPRT.^[@ref17]^ Inhibition is noncompetitive against both substrates ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B), and data fitted to [eq [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"} yielded a *K*~is~ of 22 ± 6 μM and a *K*~ii~ of 38 ± 7 μM against PRPP and a *K*~is~ of 56 ± 25 μM and a *K*~ii~ of 36 ± 5 μM against ATP. Each double-reciprocal curve was also fitted individually, and linear regression of the slope and intercept replots ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)) produced a *K*~is~ of 30 μM and a *K*~ii~ of 26 μM against PRPP and a *K*~is~ of 60 μM and a *K*~ii~ of 40 μM against ATP, in reasonable agreement with those obtained from a global fit to [eq [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"}.

![*Pa*ATPPRT inhibition by histidine. (A) Dose--response curve for histidine concentration. The line is the best fit of the data to [eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"}. (B) Double-reciprocal plots of substrate saturation curves in the presence of histidine. Lines are reciprocals of the best fit of the data to [eq [5](#eq5){ref-type="disp-formula"}](#eq5){ref-type="disp-formula"}.](bi-2019-002824_0001){#fig1}

Histidine is a noncompetitive inhibitor of other HisG~S~ ATPPRTs^[@ref22],[@ref31]^ and of HisG~L~ ATPPRTs,^[@ref3],[@ref16]^ except that from *M. tuberculosis* ATPPRT, where inhibition is uncompetitive against ATP.^[@ref17]^ The *K*~i~ values for *Pa*ATPPRT are similar to those reported for *Campylobacter jejuni*,^[@ref16]^*M. tuberculosis*,^[@ref17]^ and *Lactococcus lactis*([@ref31]) ATPPRTs but nearly an order of magnitude lower than those reported for the *Salmonella typhimurium*([@ref3]) and *T. maritima*([@ref22]) enzymes.

Low-Affinity Binding of Histidine to Free *Pa*HisZ {#sec3.2}
--------------------------------------------------

The binding of the inhibitor to free *Pa*HisZ was tested by DSF. Histidine increases the *T*~m~ of *Pa*HisZ ([Figure S2A](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)), but the apparent affinity of the inhibitor for the free regulatory subunit is low ([Figure S2B](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)), with a *K*~D~ of 2.8 ± 0.8 mM. This indicates that *Pa*HisG~S~ is not strictly necessary for the binding of histidine to *Pa*HisZ, though the hetero-octameric arrangement may be necessary to increase the affinity of the interaction.

Catalysis and Inhibition with ADP as the Substrate {#sec3.3}
--------------------------------------------------

ADP has been shown to be a substrate, replacing ATP, for non-activated *Pa*HisG~S~,^[@ref11]^ and the crystal structure of the *Pa*ATPPRT--PRPP--ADP complex suggests the same may be true for the activated enzyme.^[@ref10]^ This hypothesis is confirmed here, with ADP efficiently replacing ATP as a substrate for *Pa*ATPPRT ([Figure S3A](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)) with a *k*~cat~ of 2.6 ± 0.4 s^--1^, a *k*~cat~/*K*~M~^PRPP^ of (3.8 ± 0.4) × 10^3^ M^--1^ s^--1^, and a *k*~cat~/*K*~M~^ADP^ of (1.6 ± 0.5) × 10^3^ M^--1^ s^--1^, in ranges similar to those obtained with ATP.^[@ref20]^ In addition, histidine can inhibit the *Pa*ATPPRT reaction with ADP as the substrate ([Figure S3B](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)) with an IC~50~ of 31 ± 1 μM and an *h* of 1.32 ± 0.09, in striking agreement with the results for the reaction with ATP. This indicates that neither catalysis nor allosteric inhibition involves the interaction between Arg73 of *Pa*HisG~S~ and the γ-PO^4--^ group of ATP, which is absent when ADP replaces ATP.^[@ref10]^

Effect of Histidine on the Approach to the Steady State {#sec3.4}
-------------------------------------------------------

*Pa*ATPPRT catalysis follows an ordered mechanism in which PRPP binds first to the enzyme and involves a burst of on-enzyme PRATP formation in the first turnover followed by a lower steady-state rate dominated by product release.^[@ref11]^ When ATP and histidine are rapidly mixed with *Pa*ATPPRT preincubated with PRPP ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), the amplitude of the burst phase, whose values are 3.49 ± 0.01 and 3.11 ± 0.01 μM in the presence and absence of histidine, respectively, is unchanged within experimental error. The subsequent steady-state rates, whose values are 16.36 ± 0.01 and 7.56 ± 0.01 μM s^--1^ in the absence and presence of histidine, respectively, reflect the inhibition. This suggests the rates of binding of ATP to the *Pa*ATPPRT--PRPP complex and the subsequent on-enzyme product formation are higher than the rate of histidine binding and establishment of inhibition. Conversely, when ATP is rapidly mixed with *Pa*ATPPRT preincubated with PRPP and histidine ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), the steady-state rate (7.83 ± 0.01 μM s^--1^) shows the same level of inhibition but the burst amplitude is drastically reduced to 0.53 ± 0.01 μM, confirming that histidine can establish an equilibrium with the *Pa*ATPPRT--PRPP binary complex to inhibit the reaction before ATP binds to trigger the first turnover. This contrasts with the case for *M. tuberculosis* ATPPRT, in which the burst amplitude decreases when ATP and histidine are rapidly mixed with the enzyme.^[@ref17]^

![Rapid kinetics of histidine inhibition. (A) Effect of histidine--enzyme preincubation on the burst in product formation in the *Pa*ATPPRT reaction. Dashed lines show the linear regression of the steady-state phase, and burst amplitudes are extrapolated from the *y*-axis intercepts. (B) Time course of product formation from activated and non-activated *Pa*ATPPRT rapid kinetics in the presence and absence of histidine (left), where black lines show the linear regression of the data. The bar graph (right) represents the initial rates extracted from the time courses.](bi-2019-002824_0002){#fig2}

Histidine Does Not Lead to Dissociation of *Pa*HisG~S~ from *Pa*HisZ {#sec3.5}
--------------------------------------------------------------------

*Pa*HisG~S~ is catalytically active, albeit with reduced activity in the absence of *Pa*HisZ, while being insensitive to histidine.^[@ref20]^ Thus, the possibility that allosteric inhibition is a result of dissociation of *Pa*HisG~S~ from the *Pa*ATPPRT holoenzyme was considered, and the background rate in the presence of histidine was that of the non-activated *Pa*HisG~S~. This was interrogated by comparing the initial rates of activated and non-activated *Pa*HisG~S~ at the same concentration in the presence and absence of histidine ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). The rate of non-activated *Pa*HisG~S~ in the presence of histidine was shown by a Student's *t* test to be higher than the rate of *Pa*ATPPRT in the presence of histidine at the *p* \< 0.0031 level. This indicates that allosteric inhibition by histidine does not result from release of *Pa*HisG~S~ from *Pa*ATPPRT to yield the non-activated free *Pa*HisG~S~ rate.

Crystal Structure of the *Pa*ATPPRT--PRPP--Histidine Complex {#sec3.6}
------------------------------------------------------------

To gain insight into the structural underpinnings of *Pa*ATPPRT allosteric inhibition, the 2.65 Å resolution crystal structure of the *Pa*ATPPRT--PRPP--histidine complex was determined, and refinement statistics are listed in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf). The *Pa*ATPPRT--PRPP--histidine complex crystallized in space group *P*2~1~ with a full hetero-octamer in the asymmetric unit. Each *Pa*HisG~S~ molecule contained a PRRP molecule bound in the active site in a similar arrangement as previously found ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A).^[@ref10]^ The omit map shows clear electron density for one molecule of histidine ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B) bound along the central antiparallel β-sheet of each molecule of *Pa*HisZ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C), more than 18 Å from the nearest *Pa*HisZ--*Pa*HisG~S~ interface. No electron density for potential ligands was found in the *Pa*HisG~S~--*Pa*HisZ interface.

![Crystal structure of the *Pa*ATPPRT--PRPP--histidine complex. (A) Ribbon diagram of the *Pa*ATPPRT hetero-octamer found in the asymmetric unit. (B) Omit map at 3σ showing electron density for histidine. (C) Ribbon diagram of the *Pa*HisZ subunit with the location of the bound histidine. *Pa*HisG~S~ subunits are colored cyan, and *Pa*HisZ is colored yellow. Ligands are shown as sticks with carbon atoms matching the color of the subunits to which they are bound.](bi-2019-002824_0003){#fig3}

The structure of the *Pa*ATPPRT--PRPP--histidine complex is in sharp contrast with the only other available structure of a HisG~S~ ATPPRT bound to histidine, that from *T. maritima*, in which two molecules of histidine per molecule of HisZ are reported, both in the interface between the catalytic and regulatory subunits.^[@ref22]^ An overlay of the histidine-bound *Pa*HisZ structure described here with that of *T. maritima* and the histidine-bound HisRS from *Burkholderia thailandensis*([@ref32]) ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)) highlights the striking differences in the location of the histidine-binding sites between the two HisZ proteins. Interestingly, the binding position of histidine is almost identical in *Pa*HisZ and HisRS. The proposal that HisRS and HisZ would share a similar location for the histidine-binding site had been previously suggested,^[@ref21]^ which is now demonstrated by the current structure.

Histidine-Binding Site {#sec3.7}
----------------------

The histidine-binding site is formed solely by *Pa*HisZ residues. The inhibitor makes several polar interactions with the side chains of eight *Pa*HisZ residues ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The α-COO^--^ group of histidine contacts the *δ-*NH and *ω-*NH~2~ groups of Arg284 and the *γ-*NH~2~ group of Gln118. The histidine *α-*NH~3~^+^ group interacts via hydrogen bonds with the Tyr265 4-OH group and Ser308 and Thr78 *β-*OH groups and via a salt bridge with the Asp76 *β-*COO^--^ group. The imidazole ring of the inhibitor is anchored to the β-strand via an interaction between its *τ-*NH and Glu122 *γ-*COO^--^ and further contacts a flexible loop that also includes Tyr265 via an interaction between its *π-*N and His266 *τ-*NH. The interactions with the imidazole ring of the inhibitor must be essential for allosteric inhibition, because TIH, a histidine analogue expected to bind in a manner similar to that of histidine but whose five-membered ring does not participate in polar interactions,^[@ref9]^ has no effect on *Pa*ATPPRT catalysis ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)). Interestingly, most *Pa*HisZ residues responsible for polar contacts with the allosteric inhibitor are conserved in *T. maritima* HisZ ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)), even though histidine is not reported to bind to that site. Two of the residues, Tyr265 and His266, are replaced by glutamate and tyrosine, respectively, in *T. maritima* HisZ, which would still be able to make similar interactions as seen in *Pa*HisZ. The only significant exception is Arg284, which has no replacement capable of polar contacts in the *T. maritima* protein.

![Close-up of the histidine-binding site in *Pa*HisZ. The inhibitor and the relevant side chains are depicted as sticks, with carbons colored yellow, nitrogens blue, and oxygens red. The dashed lines represent polar contacts.](bi-2019-002824_0004){#fig4}

Structural Basis for *Pa*ATPPRT Allosteric Inhibition {#sec3.8}
-----------------------------------------------------

HisG~S~ ATPPRTs are intriguing hetero-octameric allosteric systems in which HisZ mediates allosteric activation and inhibition of catalysis by HisG~S~, depending on the presence of histidine.^[@ref6],[@ref8],[@ref20]^ The mechanism of *Pa*ATPPRT allosteric activation has recently been uncovered and involves the subunits of the *Pa*HisG~S~ dimer moving closer to one another, leading to a change in the average position of a *Pa*HisG~S~ loop that reaches across the adjacent subunit to provide leaving group stabilization at the transition state via a salt bridge between its Arg56 and the PRPP PP~i~ moiety.^[@ref10],[@ref11]^ However, this is only manifested upon binding of ATP to the *Pa*ATPPRT--PRPP binary complex, as all other structures of *Pa*ATPPRT, namely, the apoenzyme and the binary complexes with PRPP and PRATP, are in a non-activated state.^[@ref10]^ An overlay of the crystal structures of the *Pa*ATPPRT--PRPP, *Pa*ATPPRT--PRPP--histidine, and *Pa*ATPPRT--PRPP--ATP ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A) complexes resulted in Cα root-mean-square deviations (rmsds) of 0.40 Å for the first two structures but 1.71 Å for the latter two. When the *Pa*HisZ tetramers are overlaid ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B), an rmsd of 0.38 Å resulted for the first two structures and an rmsd of 1.37 Å for the latter two. An overlay of the *Pa*HisG~S~ dimers ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C) yielded an rmsd of 0.27 Å for the first two structures and 1.75 Å for the latter two. These results suggest that both *Pa*ATPPRT--PRPP and *Pa*ATPPRT--PRPP--histidine complexes are in an overall very similar non-activated conformation. However, the *Pa*ATPPRT--PRPP complex is en route to activation upon ATP binding, but histidine binding may lock the hetero-octamer in a non-activated state, preventing the conformational changes that would otherwise take place following ATP binding.

![Overlay of the structures of *Pa*ATPPRT--PRPP, *Pa*ATPPRT--PRPP--histidine, and *Pa*ATPPRT--PRPP--ATP complexes. (A) Overlay of the full hetero-octamers. (B) Overlay of the *Pa*HisZ tetramers. (C) Overlay of the *Pa*HisG~S~ dimers.](bi-2019-002824_0005){#fig5}

A Potential Structural Path for Allosteric Inhibition {#sec3.9}
-----------------------------------------------------

In an attempt to uncover how the structural rearrangements that may prevent activation of the *Pa*ATPPRT--PRPP--histidine complex are relayed from the inhibitor-binding site to the active site, *Pa*HisZ subunits from each structure (*Pa*ATPPRT,^[@ref20]^*Pa*ATPPRT--PRPP, *Pa*ATPPRT--PRPP--ATP, *Pa*ATPPRT--PRATP,^[@ref10]^ and *Pa*ATPPRT--PRPP--histidine) were overlaid over their Cα atoms ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A). The conformations of the *Pa*HisZ monomers are very similar across all structures, except for the position of two loops. The first is the histidine-binding loop (red arrow in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A), spanning residues Asp256--Ile269 ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B), in the *Pa*ATPPRT--PRPP--histidine complex, which moves \>4.5 Å from its position in all other structures ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B). This loop includes His266, whose side chain adopts a slightly different rotamer to interact with the inhibitor, and Tyr265, whose 4-OH group is \>6 Å from its position in the other structures, forming a hydrogen bond with the bound histidine ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B, yellow structure). The second (blue arrow in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A) is the loop spanning residues Asp101--Leu117 ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B), which in the structure of the activated *Pa*ATPPRT--PRPP--ATP complex is \>2 Å from its position in all other structures ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B, gray structure). These two loops are connected in the structure of the *Pa*ATPPRT--PRPP--histidine complex via a hydrogen bond between Tyr263 in the histidine-binding loop, which has rotated almost 180° from its position in all other structures, and His104 in the Asp101--Leu117 loop ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B). This interaction is missing from all other *Pa*ATPPRT structures.

![*Pa*HisZ subunit conformations across *Pa*ATPPRT structures. (A) Overlay of *Pa*HisZ subunits from all *Pa*ATPPRT structures. The red arrow points to the histidine-binding loop, and the blue arrow points to the Asp101--Leu117 loop. (B) Close-up view of the two loops, key side chains, and the inhibitor histidine. *Pa*HisZ residue side chains and bound histidine are shown as sticks. Dashed lines denote polar interactions. Black arrows highlight the different positions adopted by the same side chains in the different structures.](bi-2019-002824_0006){#fig6}

The Asp101--Leu117 loop leads directly to the *Pa*HisZ--*Pa*HisG~S~ interface and is poised for hydrophobic interactions via the side chains of its Leu110 and Phe111 residues with one of the *Pa*HisG~S~ monomers in the activated *Pa*ATPPRT--PRPP--ATP complex ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, *Pa*HisZ colored gray and *Pa*HisG~S~ colored magenta). Nonetheless, in the allosterically inhibited *Pa*ATPPRT--PRPP--histidine complex, the position of this loop is shifted toward the other *Pa*HisG~S~ monomer ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, *Pa*HisZ colored yellow and *Pa*HisG~S~ colored cyan), with *Pa*HisZ Leu110 disrupting a Glu82--His103 interaction in *Pa*HisG~S~. Furthermore, the aromatic ring of *Pa*HisZ Phe111 occupies a space closer to the interface between the two *Pa*HisG~S~ subunits ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, *Pa*HisZ colored yellow and *Pa*HisG~S~ colored cyan), further perturbing the hydrophobic interactions present in the activated complex ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, *Pa*HisZ colored gray and *Pa*HisG~S~ colored magenta). This seems to have a knock-on effect on several other residues along the *Pa*HisG~S~--*Pa*HisG~S~ interface ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, magenta and cyan), which culminates in the α-helix and β-strand connecting the loop responsible for cross-subunit stabilization of leaving group departure receding ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, cyan, indicated by black arrows) from their respective positions in the activated Michaelis complex ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, magenta) and consequently being farther from the adjacent catalytic subunit. This might be responsible, in whole or in part, for the allosteric inhibition triggered by histidine binding.

![Ribbon diagram of the *Pa*HisZ--*Pa*HisG~S~ and *Pa*HisG~S~--*Pa*HisG~S~ interface in overlaid structures of *Pa*ATPPRT--PRPP--histidine and *Pa*ATPPRT--PRPP--ATP complexes. For the sake of clarity, only part of one *Pa*HisZ and one of the *Pa*HisG~S~ dimers are shown for each structure. Side chains are shown as sticks, and substrates as wireframe. The Mg^2+^ ions in the structure of the *Pa*ATPPRT--PRPP--ATP complex are represented as green spheres. Black arrows denote the distinct positions of the *Pa*HisG~S~ loop responsible for leaving group stabilization in the transition state.](bi-2019-002824_0007){#fig7}

Amino acid multiple-sequence alignment of HisZs ([Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)) shows that Tyr263 is conserved in five sequences, and His104 in six, of 13 aligned. In two other sequences, they are replaced by residues capable of similar polar interactions. To test the hypothesis about the importance of the Tyr263--His104 interaction, the Y263F mutation was introduced into *Pa*HisZ (Y263F-*Pa*ATPPRT). Tyr263 is not part of the histidine-binding site and as such should not impact histidine binding, but the absence of the Tyr263 4-OH group will prevent the hydrogen bond between Tyr263 and His104 from forming. If this interaction is crucial for relaying the allosteric signal to the active site, then Y263F-*Pa*ATPPRT should be insensitive to inhibition by histidine. When the enzyme activity of Y263F-*Pa*ATPPRT is measured in the absence and presence of histidine ([Figure S8](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf)), significant but not complete inhibition is observed. The ratio of initial rates in the presence (*v*~i~) and absence (*v*~0~) of inhibitor (*v*~i~/*v*~0~) is 0.250 ± 0.001 for Y263F-*Pa*ATPPRT, while *v*~i~/*v*~0~ = 0.070 ± 0.004 for WT-*Pa*ATPPRT. This is consistent with the disruption of the Tyr263--His104 hydrogen bond rendering Y263F-*Pa*ATPPRT \>3-fold less susceptible than WT-*Pa*ATPPRT to inhibition by histidine, raising the possibility the interaction plays a role in mediating allostery. However, 75% of the enzyme activity of the mutant is still lost due to histidine inhibition, indicating that other factors are involved in the transmission of the allosteric signal.

These elusive factors may involve additional conformational changes triggered by histidine binding not evident in this structure. It is worth noting that crystals of the *Pa*ATPPRT--PRPP--histidine complex could be obtained only by soaking, which might hinder some conformational changes due to crystal packing. Furthermore, instead of a relatively stable conformational change, a significant portion of the allosteric signal relay may involve a transient shift in the dynamic landscape sampled by the enzyme, which would be unlikely to be captured *in crystallo*. Further studies, probably encompassing experimental and computational approaches, will be required for a complete elucidation of the allosteric inhibition pathway in short-form ATPPRTs.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.biochem.9b00282](http://pubs.acs.org/doi/abs/10.1021/acs.biochem.9b00282).Figures S1--S8 and Table S1 ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.9b00282/suppl_file/bi9b00282_si_001.pdf))
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